India, Oct. 30 -- The shares of one of the leading developers and manufacturers of select, high-value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas are in focus after it rose by 7 per cent in today's market session following the announcement of strong Q2 FY27 results, with EBITDA margins reaching a record high of 41.8%.

With a market capitalisation of Rs. 17,531 cr, the shares of Alivus Life Sciences Ltd were trading at Rs. 1428 per share, making a high of Rs. 1,497, increasing 7% in today's market session from its previous close of Rs. 1,397.75 per share.

Q2 FY27 Financial Performance Alivus Life Sciences reported a strong financial performance for the second quarter of FY27, with revenue fr...